ABSTIL4ff. We investigated the effect of captopril, an orally active angiotensin converting enzyme inhibitor, on urinary protein excretion in puromycin aminonucleoside nephrotic rats. The administration of captopril(10 mg/100 g body weight) decreased proteinuria on days 10-14 following the administration of puromycin aminonucleoside (73.0 versus 125.0 rng, p c 0.01), without affecting glomerular filtration rate. The beneficial effect of captopril was not abolished by the continuous intravenous infusion of angiotensin I1 (10 pg/kg/h for 9 days) or subcutaneous injections of aprotinin (50,000 KIU/day for 3 days). Indomethacin, in moderate (5 mg/kg/day for 3 days) or high (10 mg/ kg/day) doses, abolished the captopril attenuation in urinary protein excretion. The salutory effect of captopril was characteized by a reduction in the fractional excretion of protein without compromising the glomerular filtration rate. No difference in renal ultrastructure was noted in captopril-treated versus control animals. Captopril was ineffective in reducing urinary protein excretion in rats with adriamycin-induced glomerulopathy. W e conclude that captopril acts to reduce proteinuria in renal disease states arising from depletion of the glomerular basement membrane polyanion. The mechanism of action is postulated to be an alteration in renal hemodynamics, namely increased blood flow and a decrease in the ultrafiltration coefficient, that are the consequence of increased intrarenal prostaglandin production. (Pediatr Res 19: 828-834, 1985) Abbreviations AI, angiotensin I AII, angiotensin I1 ACE, angiotensin converting enzyme BW, body weight FEpr, fractional excretion of protein G B M , glomeruiar basement membrane GFR, glomerular filtration rate ka ultrafiltration coefficient PAN, puromycin aminonucleoside Q A , renal blood flow Many vasoactive substances are capable of altering quantitative urinary protein excretion in normal and disease states.The